TY  - GEN
AU  - Feist,Eugen
AU  - Feist,Eugen
TI  - Systemic Autoinflammatory Diseases—Clinical Rheumatic Challenges
SN  - books978-3-0365-2561-7
PY  - 2021///
CY  - Basel, Switzerland
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - Medicine
KW  - bicssc
KW  - gout
KW  - febuxostat
KW  - colchicine
KW  - hepatotoxicity
KW  - prophylaxis
KW  - myositis
KW  - inflammatory idiopathic myopathy
KW  - dysphagia
KW  - aspiration
KW  - pneumonia
KW  - immunoglobulin G4-related orbital disease (IgG4-ROD)
KW  - orbital lymphoma (OL)
KW  - computed tomography (CT)
KW  - Hounsfield unit
KW  - imaging
KW  - autoinflammation
KW  - arthritis
KW  - CAPS
KW  - FCAS
KW  - MWS
KW  - CINCA
KW  - NOMID
KW  - hearing loss
KW  - urticarial-like rash
KW  - autoinflammatory disease
KW  - anti-IL-1 treatment
KW  - rheumatoid arthritis
KW  - synovitis
KW  - neoplasms
KW  - edema
KW  - inflammation
KW  - new genetic variant
KW  - monogenic autoinflammatory syndrome
KW  - diagnostic delay
KW  - anakinra
KW  - damage index
KW  - genetic inheritance
KW  - personalized therapy
KW  - Interleukin-1
KW  - autoinflammatory diseases
KW  - FMF
KW  - coronavirus
KW  - SARS-CoV-2 antibody response
KW  - adult-onset Still’s disease
KW  - autoinflammatory disorder
KW  - systemic-onset juvenile idiopathic arthritis
KW  - haemophagocytic lymphohistiocytosis
KW  - macrophage activation syndrome
KW  - IFN-γ
KW  - JAK inhibitor
KW  - proliferation
KW  - DNA damage repair
KW  - γH2AX
KW  - PBMCs
KW  - T lymphocytes
KW  - proteasome
KW  - autoimmune
KW  - proteasome-associated autoinflammatory syndrome
KW  - therapy
KW  - IL-1 inhibitors
KW  - NGS
KW  - SURF
KW  - spondyloarthritis
KW  - human leukocyte antigen
KW  - undifferentiated enthesitis and/or arthritis
KW  - ASAS classification criteria
KW  - clinical management
KW  - canakinumab
KW  - cytokines
KW  - n/a
N1  - Open Access
N2  - Autoinflammation, as a relatively new field in clinical rheumatology, has gained an increasing importance in recent years. The number of identified entities and affected patients has gradually increased, and some of the involved pathways have already been identified. This progress allows a deeper understanding of closely linked diseases, namely, inflammasomopathies, interferonopathies, Relo-pathies, and proteasome associated syndromes. These insights have not only improved their classification but also helped to identify new treatment targets of pro-inflammatory cytokines, including IL-1ß, IL-6, interferon-, and TNF-alpha. Nevertheless, there is still a high medical need, especially in reliable outcome measures, for confirmation of data from controlled clinical trials and, finally, also for long-term experience from registers. This issue welcomes all types of papers on the broad spectrum of clinical characteristics, prognosis, pathophysiology, and treatment of autoinflammatory diseases. The goal of this Special Issue is to further raise awareness of autoinflammatory processes and to better separate them from well-established autoimmune diseases. It is clear that we have entered a new age in this complex field, linking rheumatology even closer to immunology
UR  - https://mdpi.com/books/pdfview/book/4695
UR  - https://directory.doabooks.org/handle/20.500.12854/77076
ER  -